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Systematic analysis of the IL-17 receptor
signalosome reveals a robust regulatory
feedback loop
Helena Draberova1,2,†, Sarka Janusova2,†, Daniela Knizkova1,2,†, Tereza Semberova1,2,
Michaela Pribikova1,2, Andrea Ujevic1,2, Karel Harant3, Sofija Knapkova4,5, Matous Hrdinka4,5 ,
Viola Fanfani6, Giovanni Stracquadanio6, Ales Drobek2 , Klara Ruppova2, Ondrej Stepanek2,* &
Peter Draber1,2,**
Abstract
IL-17 mediates immune protection from fungi and bacteria, as well
as it promotes autoimmune pathologies. However, the regulation of
the signal transduction from the IL-17 receptor (IL-17R) remained
elusive. We developed a novel mass spectrometry-based approach to
identify components of the IL-17R complex followed by analysis of
their roles using reverse genetics. Besides the identification of linear
ubiquitin chain assembly complex (LUBAC) as an important signal
transducing component of IL-17R, we established that IL-17 signaling
is regulated by a robust negative feedback loop mediated by TBK1
and IKKe. These kinases terminate IL-17 signaling by phosphorylating
the adaptor ACT1 leading to the release of the essential ubiquitin
ligase TRAF6 from the complex. NEMO recruits both kinases to the
IL-17R complex, documenting that NEMO has an unprecedented
negative function in IL-17 signaling, distinct from its role in NF-jB
activation. Our study provides a comprehensive view of the
molecular events of the IL-17 signal transduction and its regulation.
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Introduction
The interleukin 17 (IL-17) is a major proinflammatory cytokine
produced by Th17 cell lineage and several innate immune cell types
(Harrington et al, 2005; Park et al, 2005; Cua & Tato, 2010). Studies
of mouse models demonstrated that this cytokine is crucial for host
defense against opportunistic fungal and bacterial species (Conti
et al, 2009; Cho et al, 2010). In accord, patients impaired in IL-17
signaling suffer from chronic mucocutaneous candidiasis (Puel et al,
2011; Conti & Gaffen, 2015). On the other hand, aberrant signaling
via IL-17 promotes pathogenesis of several autoimmune disorders,
such as psoriasis, atopic dermatitis, rheumatoid arthritis, or multiple
sclerosis (Brembilla et al, 2018) and therapeutic antibodies blocking
IL-17 or its receptor have been successfully used in clinic to treat
severe plaque psoriasis (Bilal et al, 2018; Hawkes et al, 2018). Alto-
gether, IL-17 production and signal transduction must be subjected
to a tight control to allow proper immune system response when
required, yet preventing autoinflammatory diseases.
Interleukin-17 receptor (IL-17R) is composed of two widely
expressed subunits IL-17RA and IL-17RC (Toy et al, 2006; Hu et al,
2010). Binding of dimeric IL-17 leads to heterodimerization of the
receptor (Ely et al, 2009; Liu et al, 2013; Goepfert et al, 2017) and
recruitment of a cytoplasmic protein ACT1 (Chang et al, 2006; Qian
et al, 2007). ACT1 was described to enhance the expression of genes
encoding proinflammatory cytokines by stabilizing their mRNAs or
by activating downstream signaling pathways leading to the activa-
tion of their transcription (Li et al, 2019). The gene-activation path-
ways are dependent on the recruitment of E3 ubiquitin ligases from
tumor necrosis factor (TNF) receptor-associated factors (TRAFs)
family, most prominently TRAF6. TRAF6 creates non-degradative
K63-polyubiquitin linkages which serve as docking sites for a vari-
ety of signaling molecules and promote activation of downstream
signaling pathways, especially mitogen-activated protein kinase
(MAPK) or nuclear factor-jB (NF-jB) and subsequent production of
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proinflammatory cytokines (Schwandner et al, 2000; Sonder et al,
2011). However, the mechanisms promoting and regulating IL-17
signaling emanating directly from IL-17 receptor are incompletely
understood. The IL-17-induced activation of downstream pathways
is surprisingly weak in comparison with other proinflammatory
cytokines such as IL-1a or TNF, although their receptors all employ
the formation of non-degradative polyubiquitin linkages and share
multiple proximal signaling proteins (Kupka et al, 2016; Strickson
et al, 2017; Li et al, 2019; McGeachy et al, 2019). The molecular
basis for these differences is poorly defined. In addition to directly
inducing activation of signaling pathways, IL-17 can trigger stabi-
lization of mRNA transcripts via ACT1 and TRAF2/5, which regu-
late mRNA stability either directly, or by modulating the activity of
mRNA binding proteins ARID5A and HuR, splicing factor SF2, and
endoribonuclease Regnase-1 (Sun et al, 2011; Herjan et al, 2013,
2018; Somma et al, 2015; Amatya et al, 2018).
In this study, we established a novel methodical approach to
analyze the assembly of the IL-17 receptor signaling complex (IL-
17RSC) via mass spectrometry (MS), which revealed the composi-
tion of the complex and its stoichiometry, including a novel signal-
ing mediator, linear ubiquitin chain assembly complex (LUBAC).
Importantly, we uncovered a robust negative inhibitory loop medi-
ated by NEMO-recruited kinases TBK1 and IKKe that is specific for
the IL-17 pathway, explaining the enigmatic mechanism of a weak
signaling response of cells to IL-17 stimulation and showing a
unique regulatory role of NEMO in the assembly of IL-17RSC.
Results
Kinases TBK1 and IKKe are strongly and preferentially activated
upon IL-17 stimulation
We aimed to resolve the composition of the IL-17 receptor signaling
complex formed upon the binding of IL-17 to its receptors. For that
purpose, we deployed a strategy for receptor-complex analysis in
which cells were stimulated with a recombinant dimeric IL-17
(Fig EV1A–C), followed by the pull-down of the whole signaling
complex via the ligand’s tandem affinity purification tag (2xStrep-
tag and 1xFlag-tag) and MS analysis (Fig 1A). This approach offers
the possibility to isolate only ligand-engaged receptors forming
membrane-proximal signaling complexes via highly specific tandem
affinity purification without the requirement for exogenous expres-
sion of tagged proteins in target cells. As a control, the ligand was
added after the cell lysis, which did not induce assembly of the
signaling complex. The IL-17 stimulation might lead to post-transla-
tional modifications of potential contaminants that would change
their binding to the beads used for immunoprecipitation. In order to
ensure that the identified proteins are bona fide components of the
IL-17RSC, we decided for relatively strict definition of background
contaminants (as described in Table EV1).
The comparison between control and stimulated samples
revealed a very specific and highly reproducible set of proteins
recruited to IL-17RSC. In contrast to IL-17RA, we detected IL-17RC
only in stimulated but not control samples, which reflects that
murine IL-17RC binds IL-17 only when it is associated with IL-17RA
(Kuestner et al, 2007). Importantly, we identified a number of previ-
ously known components of IL-17RSC: core protein ACT1, non-
degradative ubiquitin ligases TRAF6 and TRAF2, deubiquitinase
A20 and associated adaptors ABIN1 and TAX1BP1, a kinase
complex NEMO/IKKa/IKKb, and homologous kinases TBK1 and
IKKe (Amatya et al, 2017). We also identified components of a
degradative ubiquitin ligase complex consisting of bTrCP1/2 and
Cullin1, which were previously reported to degrade ACT1 upon
prolonged stimulation (Shi et al, 2011), although it was not known
they are recruited directly to the IL-17RSC. In addition, we identified
proteins TANK and NAP1 that have not yet been connected to the
IL-17R pathway (Fig 1B and Table EV1). These two adaptors were
reported to associate with TBK1 and IKKe (Chau et al, 2008; Helga-
son et al, 2013) and recruit them to the TNFR1 signaling complex
(TNF-RSC) (Lafont et al, 2018).
We subsequently calculated the stoichiometry between individ-
ual components of the complex using intensity-based absolute quan-
tification (iBAQ) (Schwanhausser et al, 2011). Murine IL-17 binds
first strongly to IL-17RA and only subsequently can interact with IL-
17RC to form the complex in 1:2:1 stoichiometry between IL-17RA:
IL-17:IL-17RC (Ely et al, 2009; Liu et al, 2013; Goepfert et al, 2017).
As IL-17RC does not bind directly to IL-17 in the post-lysis control
samples, we normalized the iBAQ values of individual proteins to
IL-17RC (Fig 1B). Surprisingly, TBK1 and IKKe were among the
most abundant components of the complex, largely exceeding the
related kinases IKKa and IKKb that are crucial for NF-jB activation
(Fig 1C and Table EV1). We confirmed that both TBK1 and IKKe
were recruited and phosphorylated on their activation Ser172
residue (Kishore et al, 2002; Ma et al, 2012) within the IL-17RSC
(Fig EV1D). High abundance of TBK1 and IKKe in the IL-17RSC
suggested that their activation might be a major signaling event trig-
gered by IL-17 stimulation. Indeed, IL-17 strongly activated TBK1
and IKKe at a comparable or even higher level as the stimulation
with strong proinflammatory stimuli TNF or IL-1a (Fig 1D). In a
sharp contrast, NF-jB and MAPK signaling pathways were only
weakly triggered by IL-17. The same results were obtained in
human cell line HeLa (Fig EV1E). Altogether, these data established
that IL-17 shows a unique preference for strong activation of TBK1
and IKKe kinases over other signaling events.
Kinases TBK1 and IKKe negatively regulate IL-17 signaling
Although our data showed that the activation of TBK1 and IKKe is
likely the most prominent signaling event upon IL-17 stimulation,
the role of TBK1 and IKKe kinases in IL-17 signaling is highly
controversial. Ablation of IKKe or TBK1 alone was described to
weakly inhibit MAPK signaling and IL-17-mediated stabilization of
mRNA (Bulek et al, 2011; Herjan et al, 2018). In accord, stimulation
of TBK1 and IKKe DKO cells with IL-17 in the presence of TNF led
to markedly decreased transcriptional response, indicating that both
kinases are positive regulators of IL-17 signaling responses (Tanaka
et al, 2019). In striking contrast, overexpression of either TBK1 or
IKKe in cells deficient for both these kinases led to inhibition of IL-
17-induced downstream signaling (Qu et al, 2012), indicating that
they are in fact negative regulators of IL-17 signaling.
In order to resolve the controversial issue concerning the role of
these kinases in shaping IL-17 responses, we employed RNA
sequencing to analyze the transcription response following IL-17
stimulation in the presence or absence of MRT67307, a highly speci-
fic inhibitor of both TBK1 and IKKe (Clark et al, 2011a) (Table EV2
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and Fig EV2A). The comparison of unstimulated with IL-17 stimu-
lated cells showed upregulation of 65 genes, most of them being
established targets of the IL-17 signaling pathway (Fig 2A). Treat-
ment of cells with MRT67307 alone induced subtle alternations of
the transcriptome that were largely non-overlapping with the effects
of IL-17 treatment (Fig EV2B and C). However, IL-17-induced
pronounced changes in the transcriptional response of cells
pretreated with MRT67307 (Fig 2B). Specifically, the inhibition of
TBK1 and IKKe augmented the upregulation of almost all IL-17
responsive genes (Fig 2C ans D). Moreover, multiple IL-17 respon-
sive genes (such as Tnf or Cxcl2) reached the significant level of
upregulation only when the IL-17 stimulation was performed in the
presence of MRT67307 (Fig 2E). Real-time PCR analysis confirmed
that inhibition of TBK1 and IKKe markedly enhanced the IL-17-
mediated upregulation of selected target genes after 2, 4, and 8 h of
stimulation (Fig 2F and EV2D). Altogether, these data demonstrated
that TBK1 and IKKe kinase activities lead to the general inhibition of
IL-17 transcriptional responses.
In the next step, we probed the role of TBK1 and IKKe in the IL-
17-triggered proximal signaling pathways. The inhibition of TBK1
and IKKe activity dramatically enhanced the activation of NF-jB
and MAPKs (Fig 2G). Subsequently, we prepared cells deficient in
TBK1, IKKe, or both using CRISPR/Cas9 approach. Ablation of
either kinase alone led to weak suppression of responses to IL-17
A
DB
Exp. name
IL-17
IL-17RA
IL-17RC
ACT1
TRAF6
TRAF2
IKKα
IKKβ
NEMO
A20
ABIN1
TAX1BP1
Cullin1
βTrCP1/2
TBK1
IKKε
TANK
NAP1
A B C D E A B C D E
17 18 19 16 10 15 19 17 10 13
18 21 25 23 17 19 21 21 23 23
- - - - - 8 10 9 8 10
- - - - - 15 24 21 25 17
- - - - - 6 9 7 5 4
- - - - - 4 3 4 3 2
- - - - - 5 7 5 4 3
- - - - - 8 2 4 2 5
- - - - - 6 6 4 3 4
- - - - - 19 23 18 12 11
- - - - - 18 18 22 17 13
- - - - - 5 7 12 8 4
- - - - - 6 14 13 8 6
2 3 - 2 - 13 19 16 15 13
- - - - - 23 29 30 26 22
- - - - - 16 19 20 19 12
- - - - - 14 14 17 12 9
- - - - - 7 7 14 8 6
SF-IL-17
post lysis
SF-IL-17
15 min
MS analysis of IL-17RSC
P-ATF2
 (min)
IκB
0 5 1530
IL-17
P-IKKα/β
P-p105
P-JNK
P-p38
TBK1
0 5 1530
TNF
0 5 1530
IL-1α
P-IKKε
P-TBK1
P-IκB
-70
-55
-40
-70
-100
-70
-40
-40
-40
-70
-70
C Stoichiometry of IL-17RSC
IL-
17
RC
AC
T1
TB
K1
TA
NK
AB
IN
1
IK
Kε
βT
rC
P1
/2
NA
P1 A2
0
NE
MO
Cu
llin
1
TR
AF
6
TA
X1
BP
1
TR
AF
2
IK
KαIK
Kβ
Lo
g2
 iB
A
Q
 In
te
ns
ity
 
no
rm
al
is
ed
 to
 IL
-1
7R
C
 
0 
2 
4 
-2 
-4 
-6 
-8 
p<0.001
p<0.001
p<0.001
p<0.001
MS
1
2
analysis
3
IL
-1
7R
A
IL
-1
7R
C
SF-IL-17
Recruited
cytoplasmic
proteins
Actin -40
IKKε -70
15 30
iBAQ Intensity (log2)
20 25N.D.
Figure 1. Kinases TBK1 and IKKe are major components of IL-17RSC.
A Schematic representation of IL-17RSC isolation and analysis. Cells are stimulated with recombinant Strep-Flag-IL-17 (SF-IL-17) (1), which leads to the crosslinking of
its two receptor subunits and recruitment of cytoplasmic molecules (2). The whole complex is isolated upon cell lysis via tandem affinity purification of the ligand
and analyzed by MS (3).
B ST2 cells were stimulated for 15 min with SF-IL-17 (500 ng/ml), solubilized and IL-17RSC was isolated via consecutive Flag and Strep immunoprecipitation and
analyzed by MS. As a control, cells were first solubilized and SF-IL-17 was added only post-lysis. Number of identified peptides (unique + razor) and iBAQ intensities
for each protein in five independent experiments are shown.
C The stoichiometry of IL-17RSC calculated as the ratio between iBAQ intensities of individual IL-17RSC components to iBAQ intensity of IL-17RC. The recruitment of
kinases TBK1 and IKKe as compared to related kinases IKKa and IKKb is significantly enhanced. Mean from five performed MS experiments is shown, the statistical
significance was determined using unpaired two-tailed Student’s t-test.
D ST2 cells were stimulated with IL-17 (500 ng/ml), TNF (50 ng/ml), or IL-1a (50 ng/ml) for indicated time points and activation of signaling pathways was analyzed by
immunoblotting. A representative of two independent experiments is shown.
Source data are available online for this figure.
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stimulation. In contrast, deficiency in both kinases led to strikingly
enhanced activation of major signaling pathways, demonstrating
absolute functional redundancy between TBK1 and IKKe in the inhi-
bition of proximal IL-17 signaling (Fig 2H). The reconstitution of
TBK1/IKKe double knockout (DKO) cells with either wild-type
kinases TBK1 or IKKe, but not with their catalytically inactive
versions, led to a strong inhibition of signaling (Fig 2I). As previ-
ously reported (Lafont et al, 2018), the ablation of both TBK1 and
IKKe did not enhance signaling upon TNF, demonstrating that these
two kinases have a unique role in the negative regulation of the IL-
17 signaling pathway (Fig EV2E). We observed strong TBK1/IKKe
activation over a broad range of IL-17 concentrations, which corre-
lated with enhanced signaling in TBK1/IKKe DKO cells (Fig EV2F).
Finally, we confirmed that concomitant deletion of TBK1 and IKKe
or their chemical inhibition led to drastically enhanced IL-17 signal-
ing also in human HeLa cells (Fig EV2G and H). Altogether, our
experimental evidence demonstrates that TBK1 and IKKe are
strongly activated upon IL-17 stimulation to provide potent inhibi-
tion of the downstream signaling in completely redundant manner.
TBK1 and IKKe inhibit the recruitment of effector molecules into
the IL-17RSC
To elucidate the molecular mechanism of how TBK1 and IKKe
inhibit the IL-17 signaling pathway, we compared the composition
of IL-17RSC in WT and TBK1/IKKe DKO cells via MS (Table EV3).
The principal component analysis demonstrated that the absence of
these two kinases led to markedly changed IL-17RSC composition
(Fig EV3A). We observed strong enrichment of non-degradative
ubiquitin ligases TRAF6 and linear ubiquitin chain assembly
complex (LUBAC) consisting of HOIP, HOIL1, and Sharpin (Kirisako
et al, 2006; Gerlach et al, 2011; Ikeda et al, 2011; Tokunaga et al,
2011) in TBK1/IKKe DKO cells (Fig 3A–C). The observation that
LUBAC is reproducibly detectable only upon TBK1/IKKe ablation
was intriguing, since LUBAC functions as a potent activator of NF-
jB in several proinflammatory complexes, such as TNF or IL-1a
(Hrdinka & Gyrd-Hansen, 2017). Ubiquitin ligase activity of TRAF6
and LUBAC create K63- and M1-ubiquitin linkages, respectively,
which provide binding platforms for adaptors TAB 1/2/3 and
associated kinase TAK1 and NEMO that recruits kinases IKKa and
IKKb (Kupka et al, 2016). In accord, the recruitment of all these
proteins to IL-17RSC was enhanced in TBK1/IKKe DKO cells
(Figs 3A and EV3B). Interestingly, the recruitment of core adaptor
ACT1 was not affected by the absence of both kinases, although
ACT1 was not phosphorylated in TBK1/IKKe DKO cells (Fig 3A–C).
On the other hand, proteins TANK and NAP1, two adaptors, consti-
tutively associated with TBK1 and IKKe (Fig EV3C and D) were
absent, while degradative ubiquitin ligase complex bTrCP1/2-
Cullin1 and TRAF2 recruitment was diminished in TBK1/IKKe DKO
cells (Figs 3A and B, and EV3B).
Because LUBAC subunits and TAB/TAK1 complex were detected
in IL-17RSC upon ablation of TBK1/IKKe, we addressed their poten-
tial roles in the IL-17 signaling. Inhibition of TAK1 blocked the IL-
17-dependent activation of JNK and p38 both in the presence or
absence of the TBK1/IKKe inhibitor, showing that TAK1 is indis-
pensable for triggering the MAPK pathway in IL-17 signaling
(Fig 3D). Likewise, the LUBAC-deficient HOIP KO cells showed
substantially impaired activation of NF-jB both in the presence and
absence of the TBK1/IKKe inhibitor (Fig 3E) and reconstitution of
HOIP KO cells with HOIP(WT), but not an empty vector, rescued IL-
17 signaling (Fig EV3E). These data show for the first time that
LUBAC is a component of IL-17RSC promoting the activation of NF-
jB. Overall, the data demonstrate that TBK1/IKKe-mediated inhibi-
tion of IL-17 proximal signaling is mediated by restriction of the
recruitment of ubiquitin ligases TRAF6, LUBAC, and effector kinases
TAK1 and IKKa/b to the IL-17RSC.
While inhibition of TBK1/IKKe led to markedly enhanced activa-
tion of signaling and transcriptional responses (Figs 2 and EV2),
cells deficient in TBK1/IKKe did promote gene-activating signaling
pathways, but were unable to induce accumulation of target cytoki-
nes mRNA (Fig EV3F). The most probable explanation for this
apparent discrepancy is the differential recruitment of TRAF2 into
the IL-17RSC in these two scenarios. Whereas TRAF2 was depleted
from the IL-17RSC in the complete absence of TBK1/IKKe (Fig 3B),
chemical inhibition of TBK1/IKKe kinase activity augmented the
recruitment of TRAF2 to the complex (Fig 3F). The major role of
TBK1/IKKe presence for TRAF2 recruitment in IL-17RSC was
intriguing. TRAF2 is not required for IL-17-induced proximal
◀ Figure 2. TBK1 and IKKe function in redundant manner as inhibitors of IL-17-induced signaling responses.A, B ST2 cells were either left untreated (A) or pretreated with TBK1/IKKe inhibitor MRT67307 (2 lM) for 30 min (B), followed by stimulation with IL-17 (500 ng/ml) for
2 h. Transcription response induced by IL-17 stimulation as compared to unstimulated cells was analyzed by RNA sequencing. In red are transcripts considered to
be significantly changed (log2 fold change > 1 or < 1, log10 Benjamini–Hochberg adjusted P-value > 2, based on the analysis of three independent experiments;
tringle is used for transcripts with log10 adjusted P-value > 100). Names of several significantly upregulated transcripts are indicated.
C The Venn diagram representing the number of significantly changed transcripts upon IL-17 stimulation detected in (A) and (B).
D, E Comparison of IL-17-induced transcriptional response in the presence or absence of TBK1/IKKe inhibitor. (D) Transcripts that are significantly changed in both
conditions. (E) Transcripts that pass significance threshold for induction only in the presence of TBK1/IKKe inhibitor. Dashed lines indicate significantly upregulated
transcripts (log2 fold change > 1); red lines separate transcripts that are more upregulated upon IL-17 stimulation in the presence of TBK1/IKKe inhibitor as
compared to IL-17 alone.
F ST2 cells pretreated or not with TBK1/IKKe inhibitor MRT67307 (2 lM) were left unstimulated or stimulated with IL-17 (500 ng/ml) for 2 h and induction of mRNA
for selected genes was analyzed by real-time PCR. Mean + SEM from five independent experiments is shown, and statistical significance was determined using
unpaired two-tailed Student’s t-test.
G ST2 cells were pretreated or not with TBK1/IKKe inhibitor MRT67307 (2 lM), stimulated with IL17 (500 ng/ml) for indicated time points and analyzed by
immunoblotting.
H ST2 wild-type, TBK1 KO, IKKe KO, or cells lacking both kinases (DKO) were stimulated with IL-17 (500 ng/ml) as indicated and analyzed by immunoblotting.
I TBK1/IKKe DKO cells reconstituted with either wild-type or kinase dead mutant (K38A) version of both kinases were stimulated with IL-17 (500 ng/ml) as indicated
and analyzed by immunoblotting.
Data information: Immunoblot results are representative of four (G) or three (H, I) independent experiments.
Source data are available online for this figure.
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signaling; however, it promotes stabilization of target transcripts via
several proteins regulating mRNA stability (Sun et al, 2011; Herjan
et al, 2013, 2018; Somma et al, 2015; Amatya et al, 2018).
Altogether, our data show that TBK1/IKKe kinases have a dual
role in IL-17RSC function: (i) Enzymatic activity of TBK1/IKKe leads
to the inhibition of TRAF6 recruitment and markedly decreased
MAPK and NF-jB signaling, while (ii) kinase activity-independent
adaptor role of TBK1/IKKe promotes recruitment of TRAF2, a regu-
lator of mRNA stability of proinflammatory cytokines (Swaidani
et al, 2019).
TBK1 and IKKe are recruited to TRAF6-generated ubiquitin
linkages via NEMO
To elucidate the molecular mechanism underlying the TBK1 and
IKKe function, we addressed how these kinases are recruited into
the IL-17RSC. First, we observed that cells deficient in ACT1, the
very proximal IL-17R-interacting protein (Chang et al, 2006; Qian
et al, 2007), show completely disrupted IL-17RSC formation (Fig 4A
and Table EV4) and disabled the activation of TBK1 and IKKe upon
IL-17 stimulation (Fig EV4A). The main role of ACT1 is to recruit
and activate a non-degradative E3 ubiquitin ligase TRAF6 (Sch-
wandner et al, 2000). Accordingly, the presence of both ACT1 and
TRAF6 is crucial for the recruitment of TBK1, IKKe, and associated
adaptors TANK and NAP1 to IL-17RSC and activation of both
kinases (Figs 4B and EV4B). To elucidate whether TRAF6 enzymatic
activity is necessary for the recruitment of these molecules, we
reconstituted TRAF6 KO cells with either wild-type TRAF6(WT) or
enzymatically inactive TRAF6(C70A) mutant and analyzed the
composition of IL-17RSC via MS. The formation of the IL-17RSC
was largely disrupted in cells expressing the enzymatically inactive
TRAF6(C70A) including the recruitment and activation of TBK1 and
IKKe. We also noted that TRAF6 enzymatic activity was necessary
for the recruitment of the inhibitory deubiquitinase A20 (Figs 4C
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Figure 3. Kinases TBK1 and IKKe modulate the composition of IL-17RSC.
A, B ST2 wild-type or TBK1/IKKe DKO cells were stimulated for 15 min with SF-IL-17 (500 ng/ml) and solubilized and IL-17RSC was isolated via consecutive Flag and
Strep immunoprecipitation and analyzed by MS. (A) The heat map shows the row-normalized Z-Score calculated from log2 transformed iBAQ intensities from five
independent experiments. (B) The ratio between iBAQ intensities of selected IL-17RSC components to iBAQ intensity of IL-17RC. Mean + SEM from five independent
experiments is shown, and statistical significance was determined by two-tailed Mann-Whitney test.
C ST2 wild-type or TBK1/IKKe DKO cells were stimulated with SF-IL-17 (500 ng/ml) for 15 min or were left unstimulated and IL-17 was added post-lysis. Lysates were
subjected to anti-Flag immunoprecipitation to isolate IL-17RSC and samples were analyzed by immunoblotting. ACT1 phosphorylation detected as upper band in
WT cells is absent in TBK1/IKKe DKO cells.
D Cells were pretreated with TAK1 inhibitor 7-oxozeanol (2 lM) and/or TBK1/IKKe inhibitor MRT67307 (2 lM), stimulated with IL-17 (500 ng/ml) for indicated time
points and lysates were analyzed by immunoblotting.
E ST2 wild-type or HOIP-deficient cells were pretreated with TBK1/IKKe inhibitor MRT67307 (2 lM), stimulated with IL-17 (500 ng/ml) as indicated, solubilized, and
analyzed by immunoblotting. *indicates unspecific band.
F ST2 cells pretreated or not with TBK1/IKKe inhibitor MRT67307 were stimulated with SF-IL-17 for 15 min or were left unstimulated and IL-17 was added post-lysis.
IL-17RSC was isolated and analyzed via immunoblotting.
Data information: Immunoblot results are representative of two (F), three (C, D) or four (E) independent experiments.
Source data are available online for this figure.
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and D, and EV4C and Table EV4). A20 was previously shown to
modulate IL-17 signaling, but was proposed to bind directly to IL-
17RA (Garg et al, 2013). However, our data imply that A20 complex
is recruited via non-degradative polyubiquitin linkages. Interest-
ingly, TRAF6(C70A) recruitment to IL-17RSC was markedly
enhanced in comparison with TRAF6(WT) (Fig 4D), further demon-
strating that IL-17RSC assembly is regulated by potent negative feed-
back loop that is triggered downstream of TRAF6 activation.
The recruitment of TBK1 and IKKe to TNF-RSC requires linear
ubiquitin linkages synthetized by LUBAC (Lafont et al, 2018; Xu
et al, 2018). In contrast, our data show that LUBAC is only very
weakly recruited to IL-17RSC and the knockout of HOIP, the main
enzymatic subunit of LUBAC, did not prevent the activation of
TBK1 and IKKe via IL-17 (Fig EV4D). These data show that TRAF6,
but not LUBAC, activity is indispensable for TBK1 and IKKe activa-
tion via IL-17. Indeed, cells lacking the TRAF6 enzymatic activity
are completely unresponsive to IL-17 even in the presence of TBK1
and IKKe inhibitor (Fig 4E and F).
NEMO is crucial for the recruitment of IKKa and IKKb to a vari-
ety of signaling complexes. However, it was also shown to recruit
TANK and NAP1 to the M1-ubiquitin chains in the TNF-RSC (Char-
iot et al, 2002; Lafont et al, 2018). Since NEMO binds to TRAF6-
mediated K63-ubiquitin as well (Ea et al, 2006; Wu et al, 2006;
Laplantine et al, 2009), we hypothesized that NEMO recruits TANK
and NAP1 adaptors bound to TBK1 and IKKe to the IL-17RSC.
Indeed, NEMO-deficient cells failed to efficiently activate TBK1 and
IKKe upon IL-17 stimulation (Fig 4G). Accordingly, the recruitment
of these kinases and their activation within IL-17RSC was reduced
by approximately 80% in the absence of NEMO in both murine and
human cell lines as revealed by the quantification of Western blots
(Figs 4H and I, and EV4E and F). Activation of TBK1/IKKe upon IL-
17 signaling was rescued in NEMO KO cells reconstituted with
NEMO(WT), but not NEMO(D201–248) lacking TANK/NAP1-
binding domains (Chariot et al, 2002; Lafont et al, 2018) or an
empty vector (Fig EV4G). Altogether, NEMO is the major protein
connecting TBK1 and IKKe with K63-linkages formed by TRAF6.
TBK1 and IKKe activation requires phosphorylation of Ser172
located in the kinase domain activation loop, which can be medi-
ated either by TBK1/IKKe themselves or by IKKa/b (Ma et al, 2012;
Larabi et al, 2013). In accord, only combined inhibition of IKKa/b
and TBK1/IKKe kinases prevented TBK1/IKKe phosphorylation,
while inhibition of IKKa/b alone or their upstream kinase TAK1 had
no apparent effect (Fig EV4H). These results provide further
evidence that NEMO-associated kinases IKKa/b might contribute to,
but are not essential for, TBK1/IKKe activation.
NEMO has unprecedented dual role in the IL-17 signaling
An interesting prediction of our model of proximal IL-17 signaling is
that NEMO has a dual role in the IL-17 signaling as it acts both as a
positive regulator by recruiting IKKa/b effector kinases and a nega-
tive regulator by recruiting TBK1/IKKe to the IL-17RSC. To test this
hypothesis, we compared the IL-17RSC composition in WT and
NEMO KO cells via MS (Table EV5). NEMO deficiency dramatically
changed the composition of IL-17RSC (Fig EV5A). In NEMO KO
cells, the kinases IKKa and IKKb were absent from IL-17RSC, while
the recruitment of TBK1 and IKKe was substantially decreased.
Moreover, these cells exhibited strongly enhanced recruitment of
TRAF6 (8.4-fold) and TAB/TAK1 complex to the IL-17RSC
(Figs 5A–C and EV5B). In contrast, ACT1 recruitment was only very
slightly increased (1.2-fold), although its phosphorylation was not
detectable (Fig 5B and C). Reconstitution of NEMO KO cells with
NEMO(WT) enabled the recruitment of phosphorylated TBK1 and
IKKe to the IL-17RSC, leading to the phosphorylation of ACT1 and
decreased recruitment of TRAF6, similarly to WT cells. In contrast,
NEMO(D201–248) lacking the TANK/NAP1 interaction site was
unable to rescue the phenotype (Fig EV5C).
Subsequently, we analyzed the IL-17 signaling pathways in WT
and NEMO KO cells. Whereas the NF-jB pathway was abolished,
the activation of MAPKs, JNK, and p38 was strongly enhanced in
NEMO KO cells compared to WT cells (Fig 5D). In accord, the
reconstitution of NEMO KO cells with NEMO (WT), but not with
NEMO (D201–248) or an empty vector, inhibited the activation of
the MAPK pathway by IL-17 (Fig EV5D). Moreover, the inhibition of
TBK1 and IKKe had no effect in NEMO-deficient cells, demonstrating
that NEMO is critical for the function of these kinases in IL-17
signaling (Fig EV5E). We confirmed that NEMO negatively regulates
the recruitment of TRAF6 into the IL-17RSC and the IL-17-triggered
MAPK activation also in human HeLa cells (Fig EV5F–H).
The negative role of NEMO in the IL-17-induced MAPK activation
was independent of its well established role in the IKKa and IKKb
activation, because the chemical inhibition of these two kinases had
no effect on the JNK and p38 activation (Fig 5E). Importantly,
NEMO deficiency does not enhance the activation of JNK and p38
upon stimulation with TNF (Fig 5F). Altogether, our experiments
identified a unique negative feedback loop in the proximal IL-17
signaling pathway, represented by NEMO-mediated recruitment of
TBK1 and IKKe to the IL17-RSC causing a release of the key ubiqui-
tin ligase TRAF6 from the complex (Fig 5G).
Phosphorylation of ACT1 by NEMO-recruited TBK1 and IKKe on
multiple residues inhibits TRAF6 recruitment
The absence of NEMO or both TBK1 and IKKe does not affect the
recruitment of ACT1, but increases the amount of TRAF6 in the IL-
17RSC both in murine and human cells (Figs 3–5 and EV6A).
Accordingly, the chemical inhibition of TBK1 and IKKe enhanced
TRAF6 recruitment to the IL-17RSC (Figs 3F and EV6B). TBK1/IKKe
activity correlates with ACT1 phosphorylation upon IL-17 stimula-
tion (Figs 3C, 4B, 4D, and 5C and EV5C). ACT1 was shown to be
degraded upon prolonged IL-17 stimulation via Cullin1-dependent
mechanism (Shi et al, 2011). Although our data show that ablation
of TBK1/IKKe leads to decreased recruitment of Cullin1 to IL-17RSC
(Figs 3A and EV3B), we did not observe increased phosphorylation
of p38 and JNK in Cullin1 KO cells upon IL-17 stimulation, even
though Cullin1-mediated degradation of IjB was inhibited
(Fig EV6C and D). Therefore, a different mechanism inhibiting
TRAF6 recruitment to IL-17RSC must be responsible for the inhibi-
tory effect of TBK1/IKKe-mediated ACT1 phosphorylation.
ACT1 associates with IL-17R via its C-terminal SEFIR domain
(Chang et al, 2006; Liu et al, 2011) and interacts with TRAF6 via its
first 15 N-terminal amino acids (Sonder et al, 2011) (Fig 6A). In
accord, the reconstitution of ACT1-deficient cells with a series of
deletion mutants demonstrated that deletion of first 20 amino acids
of ACT1 completely prevented IL-17 signaling (Fig EV6E). Interest-
ingly, the analysis of ACT1 structure in silico (Mizianty et al, 2013;
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Hanson et al, 2017; Meszaros et al, 2018) indicated that the mid-
part separating TRAF6-binding site and the SEFIR domain is highly
disordered (Fig 6B). Our MS data revealed that ACT1 in the IL-
17RSC was phosphorylated at multiple sites, all of them being
within the unstructured mid-part (Fig 6A and Table EV6). Further-
more, none of the phospho-sites is located in the close proximity to
the TRAF6-binding domain, raising a question how these
phosphorylation events affect TRAF6 recruitment. The reconstitu-
tion of ACT1-deficient cells with ACT1 protein mutated in individual
phospho-sites to alanines did not affect the signaling outcome
(Fig 6C), suggesting that there is not a single critical phospho-site in
ACT1. However, mutation of all these phospho-sites substantially
increased signaling responses to IL-17 (Fig 6D) and strongly
enhanced recruitment of TRAF6 to IL-17RSC (Fig 6E). Altogether,
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these data showed that TBK1 and IKKe phosphorylate ACT1 at
multiple sites in the disordered mid-part of the protein to limit the
amount of recruited TRAF6. In accord, reconstitution of ACT1 KO
cells with ACT1 (D20–380) deletion mutant led to markedly
enhanced proximal signaling as compared to ACT1(WT) (Fig 6F).
Based on these data, we propose a new model of IL-17RSC
formation and regulation. Triggering of the IL-17RA/IL-17RC by
dimeric IL-17 leads to the recruitment of approximately six ACT1
molecules as evident from our MS analysis (Fig 6G). These accumu-
lated ACT1 molecules provide multiple TRAF6-binding sites, gener-
ating a high-avidity docking site for TRAF6 trimers (Ye et al, 2002).
TRAF6-mediated K63-ubiquitin chains promote the recruitment and
activation of effector molecules and kinases TBK1 and IKKe via
NEMO. TBK1/IKKe have dual role: on one hand, they recruit TRAF2
in a kinase activity-independent manner that is not required for acti-
vation of proximal signaling pathways, but promotes expression of
target genes by stabilization of their transcripts. On the other hand,
TBK1 and IKKe phosphorylate ACT1 at multiple sites within its
unstructured mid-part separating SEFIR- and TRAF6-binding
domains. This results in a strong negative charge-mediated repul-
sion between individual ACT1 molecules. Subsequently, individual
TRAF6-binding domains are separated leading to the release of
TRAF6 trimers from the complex (Fig 7). In this manner, NEMO-
mediated recruitment of TBK1 and IKKe kinases provide a potent
negative feedback loop, which limits the IL-17 signaling pathway.
Discussion
Proper regulation of IL-17RSC assembly and signaling is crucial for
efficient immune responses while preventing autoimmunity. Our
study provides a new methodological approach to analyze the
assembly of the early signaling complex formed immediately upon
binding of IL-17 to its receptors. Based on this methodology, we
identified two kinases, TBK1 and IKKe, as major components of the
IL-17RSC, whose recruitment is over 50-fold increased when
compared with related kinases IKKa and IKKb. We demonstrated
that these kinases are very strongly activated upon IL-17
stimulation, to levels comparable with strongly proinflammatory
cytokines IL-1a or TNF.
The role of these kinases in IL-17 signaling has been very contro-
versial. Two highly influential studies showed that the ablation of
either TBK1 or IKKe alone inhibited IL-17 transcriptional responses
(Bulek et al, 2011; Herjan et al, 2018). These articles promoted the
view that these kinases have an activation role (Monin & Gaffen,
2018; Li et al, 2019; McGeachy et al, 2019; Swaidani et al, 2019). In
accord, a recent publication analyzing the transcriptional response
of cells upon IL-17 stimulation in the presence of TNF demonstrated
that deficiency of TBK1/IKKe led to markedly low activation of tran-
scription, again supporting the view that these kinases propagate IL-
17 signaling (Tanaka et al, 2019). However, cells deficient in TBK1/
IKKe are highly prone to TNF-induced cell death (Bonnard et al,
2000; Matsui et al, 2006; Lafont et al, 2018; Xu et al, 2018) and it
has been shown that mouse embryonic fibroblast deficient in TBK1/
IKKe, used by Tanaka et al, rapidly succumb to TNF-induced apop-
tosis and necroptosis (Lafont et al, 2018). Therefore, the irrespon-
siveness of TBK1/IKKe DKO cells to a combined IL-17 and TNF
treatment can be explained by their death.
On the other hand, another study described that overexpression
of TBK1 or IKKe in TBK1/IKKe DKO cells inhibits the IL-17 signaling
via reducing the recruitment of TRAF6 to ACT1 (Qu et al, 2012).
However, these experiments relied on overexpression systems and
the molecular mechanism explaining the observed phenotype was
only partially uncovered. Perhaps, this is why this study is either
ignored or misinterpreted in a number of recent reviews on the topic
of IL-17 signaling (Gaffen et al, 2014; Monin & Gaffen, 2018; Li et al,
2019; McGeachy et al, 2019; Swaidani et al, 2019). In this study, we
resolved the controversy and developed a model explaining the role
of TBK1 and IKKe in regulation of IL-17RSC assembly and signaling.
The core of IL-17RSC contains dimeric IL-17, one IL-17RA and one
IL-17RC subunits (Ely et al, 2009; Liu et al, 2013; Goepfert et al,
2017). Our data demonstrated that this complex then recruits on aver-
age six ACT1 molecules. The molecular basis for ACT1 enrichment is
presently unclear. ACT1 was described to form homo-oligomers
(Mauro et al, 2003; Liu et al, 2011; Boisson et al, 2013) and it is possi-
ble that once ACT1 is recruited, it can provide docking sites for
◀ Figure 4. Enzymatic activity of TRAF6 and NEMO is crucial for the recruitment of both TBK1 and IKKe to IL-17RSC.A ST2 wild-type and ACT1-deficient cells were stimulated for 15 min with SF-IL-17 (500 ng/ml) and solubilized and IL-17RSC was isolated via consecutive Flag and
Strep immunoprecipitation and analyzed by MS. As a control, cells were first solubilized and SF-IL-17 was added only post-lysis. Number of identified peptides
(unique + razor) and iBAQ intensities for each protein in two independent experiments are shown.
B ST2 wild-type, ACT1 KO or TRAF6 KO cells were stimulated with SF-IL-17 (500 ng/ml) as indicated or were left unstimulated and IL-17 was added post-lysis. Lysates
were subjected to anti-Flag immunoprecipitation to isolate IL-17RSC and samples were analyzed by immunoblotting.
C ST2 cells deficient in TRAF6 reconstituted with TRAF6(WT) or enzymatically inactive TRAF6(C70A) were stimulated for 15 min with SF-IL-17 (500 ng/ml), solubilized
and IL-17RSC was isolated via consecutive Flag and Strep immunoprecipitation and analyzed by MS. Number of identified peptides (unique + razor) and iBAQ
intensities for each protein in two independent experiments are shown.
D TRAF6-deficient cells reconstituted with TRAF6(WT), TRAF6(C70A), or empty vector were stimulated with SF-IL-17 (500 ng/ml) as indicated or were left unstimulated
and IL-17 was added post-lysis. IL-17RSC was isolated from lysates by anti-Flag immunoprecipitation and analyzed by immunoblotting. Short and long exposure of
the same membrane stained for Act1 are shown for lysate and IP samples, respectively.
E, F TRAF6-deficient cells reconstituted with the indicated constructs were pretreated or not with TBK1/IKKe inhibitor MRT67307 (2 lM) and stimulated with IL-17
(500 ng/ml) for indicated time. (E) The activation of signaling pathways analyzed by immunoblotting. (F) The induction of mRNA for selected genes analyzed by
real-time PCR. Mean + SEM from four independent experiments is shown, and statistical significance was determined using unpaired two-tailed Student’s t-test.
G ST2 cells wild-type or NEMO KO were stimulated with IL-17 (500 ng/ml) for indicated time points and solubilized and analyzed by immunoblotting.
H, I ST2 wild-type or NEMO KO cells were stimulated with SF-IL-17 (500 ng/ml) as indicated or were left unstimulated and IL-17 was added post-lysis. Lysates were
subjected to anti-Flag immunoprecipitation to isolate IL-17RSC. Samples were analyzed by immunoblotting (H). In addition, results from four independent
experiments were quantified by densitometry and mean + SEM from four independent experiments is shown (I).
Data information: Immunoblot results are representative of two (B, E), three (D), or four (G–I) independent experiments.
Source data are available online for this figure.
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additional ACT1 molecules. The enrichment of ACT1 proteins in the
complex provides multiple binding sites for trimeric K63-ubiquitin
ligase TRAF6. Importantly, TRAF6 has relatively low affinity to mono-
meric scaffolds (Ye et al, 2002) and oligomerization of ACT1 likely
enables high-avidity interactions, which explains the molecular mech-
anism of TRAF6 enrichment at the IL-17RSC. The recruitment of
TRAF6 seems to be absolutely critical for IL-17RSC assembly, since the
ablation of TRAF6 or its enzymatic activity prevented recruitment of
all other components of the complex. Analysis of various complexes
dependent on formation of K63-linkages for signaling showed a similar
pattern of molecules that are recruited via binding to polyubiquitin
linkages, including signaling complexes like TAB/TAK1 and NEMO/
IKKa/IKKb (Zinngrebe et al, 2014; Shimizu et al, 2015). However,
these molecules are recruited very weakly to IL-17, which correlates
with poor signaling response of cells upon IL-17 stimulation.
The canonical role of NEMO in IL-17 and other signaling path-
ways is the recruitment and activation of IKKa/IKKb kinases to
trigger NF-jB pathway (Hinz & Scheidereit, 2014). Here, we
revealed an unexpected dual role of K63-ubiquitin binding adaptor
NEMO in IL-17 signaling. NEMO recruits adaptors TANK and NAP1
which in turn bring two closely related kinases TBK1 and IKKe to
IL-17RSC, similarly to its role in TNF-RSC (Clark et al, 2011b; Lafont
et al, 2018). TBK1/IKKe are recruited to various signaling
complexes, and depending on the particular context, they can
modulate various cellular processes, ranging from the induction of
mitophagy and autophagy (Wild et al, 2011; Heo et al, 2015; Thur-
ston et al, 2016), interferon signaling (Fitzgerald et al, 2003; Sharma
et al, 2003; Perry et al, 2004) to the protection from TNF-induced
cell death (Bonnard et al, 2000; Lafont et al, 2018; Xu et al, 2018).
Our data revealed that in the case of IL-17RSC assembly, TBK1
and IKKe trigger a robust negative feedback loop by phosphorylating
ACT1 on a number of residues in a long unstructured stretch of
amino acids separating SEFIR domain and the TRAF6-binding site.
The sites identified in this study are partially different from previous
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Figure 5. NEMO functions as an inhibitor of IL-17RSC assembly.
A, B ST2 wild-type or NEMO KO cells were stimulated for 15 min with SF-IL-17 (500 ng/ml), solubilized and IL-17RSC was isolated via consecutive Flag and Strep
immunoprecipitation and analyzed by MS. (A) The heat map shows the row-normalized Z-Score calculated from log2 transformed iBAQ values from two
independent experiments. (B) The ratio between iBAQ intensities of selected IL-17RSC components to iBAQ intensity of IL-17RC. Mean + SEM from two
independent experiments is shown.
C, D ST2 wild-type or NEMO KO cells were stimulated with SF-IL-17 (500 ng/ml) as indicated or were left unstimulated and IL-17 was added post-lysis. Lysates were
subjected to anti-Flag immunoprecipitation to isolate IL-17RSC (C) or tested for activation of signaling pathways (D) and analyzed by immunoblotting.
E ST2 cells were pretreated with TBK1/IKKe inhibitor MRT67307 (2 lM) or IKKa/IKKb inhibitor TPCA1 (10 lM), stimulated with IL-17 (500 ng/ml) as indicated and
analyzed by immunoblotting.
F ST2 wild-type or NEMO KO cells were stimulated with TNF (50 ng/ml) for indicated time points and lysates were analyzed by immunoblotting.
G Schematic model of the negative feedback loop mediated by NEMO-recruited TBK1/IKKe.
Immunoblot results are representative of four (C, D), three (E), or two (F) independent experiments.
Source data are available online for this figure.
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reports (Bulek et al, 2011; Qu et al, 2012), which might reflect
either differences in the experimental setup or in the cell lines used.
However, our data indicate that phosphorylation of any of the phos-
phorylation sites within this part of ACT1 contributes to the spatial
separation of TRAF6-binding sites, leading to decreased avidity of
TRAF6 for ACT1 oligomers and its release from the IL-17RSC. This
mechanism limits the ability of TRAF6 to create K63-ubiquitin link-
ages and promote recruitment of additional effector molecules, but
still ensures that some basal signaling is triggered. The inhibitory
role of NEMO mediated by the recruitment of TBK1/IKKe is
unprecedented as it has not been described previously and it
currently seems to be unique for IL-17. The ablation of the TBK1/
IKKe-mediated negative feedback loop completely changes the
composition of the receptor by enhancing the recruitment of ubiqui-
tin-binding proteins, which allows the detection of signaling compo-
nents such as LUBAC and TAB/TAK1. LUBAC amplifies signaling
by recruiting additional NEMO/IKKa/IKKb and enhancing NF-jB
activation (Kirisako et al, 2006; Haas et al, 2009; Tokunaga et al,
2009; Hrdinka & Gyrd-Hansen, 2017), which is reflected in markedly
enhanced transcription of IL-17 target genes.
At the same time, TBK1/IKKe recruit TRAF2 in a kinase activity-
independent manner, which is required for the expression of IL-17
responsive genes via stabilization of their transcripts (Sun et al,
2011; Herjan et al, 2013, 2018; Somma et al, 2015; Amatya et al,
2018). The exact molecular mechanism of how TRAF2 is recruited
to the IL-17RSC remains to be resolved, although both TBK1 and
IKKe were shown previously to associate with TRAF2 (Pomerantz &
Baltimore, 1999; Bonnard et al, 2000; Shen et al, 2012). Interest-
ingly, we did not detect TRAF5, another reported regulator of mRNA
stability (Sun et al, 2011), in the IL-17RSC. One possibility is that
the recruitment of TRAF5 to the complex might be weak or transient
and below the detection limit of our method. Altogether, TBK1/IKKe
kinases are major regulators of the complex and modulate its func-
tion. They inhibit recruitment of TRAF6 and therefore induction of
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Figure 6. Phosphorylation of ACT1 in disordered region leads to the release of TRAF6 from IL-17RSC.
A Schematic representation of ACT1 with indicated TRAF6-binding domain, SEFIR domain and location of phosphorylation sites identified in our MS analysis (based
on Table EV6).
B Analysis of ACT1 structure using three different algorithms predicting disordered regions. Detected phosphorylation sites are all in the disordered region of the
protein.
C, D ACT1 KO cells were reconstituted with either wild-type ACT1 or indicated mutants or ACT1 with all nine identified phospho-sites mutated to alanines (9ST mut).
Cells were stimulated with IL-17 (500 ng/ml) as indicated and lysates were analyzed by immunoblotting. *indicates nonspecific band.
E ACT1 KO cells expressing either ACT1(WT) or ACT1(9ST mut) were stimulated with SF-IL-17 (500 ng/ml) as indicated or were left unstimulated and IL-17 was added
post-lysis. IL-17RSC was isolated via anti-Flag immunoprecipitation and analyzed by immunoblotting.
F ACT1 KO cells were reconstituted with either ACT1(WT) or ACT1 (D20–380). Cells were stimulated with IL-17 (500 ng/ml) as indicated and lysates were analyzed by
immunoblotting. *indicates nonspecific band.
G Analysis of iBAQ intensity of ACT1 normalized to iBAQ intensity of IL-17RC. Data are composite of all 14 MS analyses of IL-17RSC from wild-type ST2 cells
performed in this study. Mean + SEM is shown.
Data information: Immunoblot results are representative of two (C, E) or four (D, F) independent experiments.
Source data are available online for this figure.
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signaling, while they promote recruitment of TRAF2 to promote
expression of IL-17 responsive genes. These results reconcile vari-
ous seemingly contradictory findings concerning the role of TBK1/
IKKe as both activators and inhibitors of signaling. The present
biochemical data were not yet confirmed using in vivo animal
models. However, the results presented in this work showing that
inhibition of TBK1/IKKe leads to massively enhanced IL-17-induced
signaling in both human and murine cell lines argue against poten-
tial therapeutic targeting of TBK1/IKKe kinase activity in treatment
of IL-17 mediated autoimmune diseases.
Our data identified a molecular mechanism for activation and
regulation of IL-17 signaling. The NEMO-TBK1/IKKe-mediated nega-
tive feedback loop allows only weak transcriptional response to IL-
17 stimulation. Given the major role of IL-17 in orchestrating the
function of the immune system, the tight control of IL-17-induced
signaling via the NEMO-TBK1/IKKe axis contributes to balancing
the efficient immune response to pathogens and self-tolerance.
Materials and Methods
Cell lines, reagents, and antibodies
ST2 cells were kindly provided by Jana Balounova (Institute of
Molecular Genetics, Prague). HeLa, Hek293, and ØNX-Eco, and
ØNX-Ampho cells were kindly provided by Tomas Brdicka (Institute
of Molecular Genetics, Prague). Cells were cultivated in DMEM
supplemented with 10% fetal calf serum (FCS; Gibco), 100 U/ml
penicillin (BB Pharma), 100 lg/ml streptomycin (Sigma-Aldrich),
and 40 lg/ml gentamicin (Sandoz). Cells were regularly tested for
mycoplasma contamination. Murine and human IL-1a and murine
TNF were purchased from Peprotech. Human TNF was produced as
described previously (Draber et al, 2015). Inhibitors MRT67307, 7-
oxozeanol, and TPCA-1 were from Tocris.
Primary antibodies used in this study were purchased from Cell
Signaling: TBK1 (Cat#3013), P-TBK1(S172) (D52C2, Cat#5483),
murine IKKe (D61F9, Cat#3416), human IKKe (D20G4, Cat#2905),
P-IKKe (S172) (D1B7, Cat#8766), P-IKKa/b (S176/180) (16A6,
Cat#2697), IjB (Cat#9242), P-IjB (Ser32/36) (5A5, Cat#9246), P-
p105 (Ser933) (18E6, Cat#4806), P-p38 (Thr180/Tyr182) (D3F9,
Cat#4511), P-JNK (Thr183/Tyr185) (98F2, Cat#4671), P-ATF2
(Thr71) (Cat#9221), P-p65 (Ser536) (93H1, Cat#3033), TANK
(Cat#2141), Myc (9B11, Cat#2276), TRAF2(C192, Cat#4724); from
Abcam: NAP1/AZI2 (EPR14698, Cat#ab192253), TRAF6 (EP592Y,
Cat#ab40675); from Santa Cruz: ACT1 (D-11, Cat#sc-398161),
NEMO (FL-419, Cat#sc-8330); from Sigma: Flag (M2, Cat#F3165),
Actin (AC-15, Cat#A1978); from MRC PPU: HOIP (S174D); HOIL1
(S150D); from ProteinTech: Sharpin (Cat#14626-I-AP), and from
BioLegend: Flag-APC (L5, Cat#637307).
Generation of knockout cell lines
In order to generate knockout cell lines via CRISPR/Cas9 approach,
single-guided RNA (sgRNA) targeting selected genes were designed
using web tool CHOPCHOP (Labun et al, 2019) and inserted in
pSpCas9(BB)-2A-GFP (PX458) vector kindly provided by Feng
Zhang (Addgene plasmid #48138) (Ran et al, 2013). All constructs
were sequenced. Below is the list of sgRNA target sequences with
highlighted PAM motif (in bold and underlined) used to knockout
different murine or human proteins:
Mouse TBK1 KO: 50-GGAAGTCCATACGCATTGGACGG
Mouse IKKe KO: 50-GGCTGGCATGAACCACCTGCGGG
Mouse IKKe in TBK1/IKKe DKO: 50-GGGCCCACCGAAGGGGAT-
GAAGG
Mouse HOIP KO: 50-GATGGATTGAGTTTCCCCGAAGG
Mouse ACT1 KO: 50-GTGGCCAAGAGATGATGCCCCGG
Mouse TRAF6 KO: 50-GCGTAAAGCCATCAAGCAGATGGG
Mouse NEMO KO: 50-GTGCATTTCCAGGTCAGCCAGCGG
Mouse Cullin1 KO: 50-GTGCCTACCTCAATAGACATTGG
Human TBK1 KO: 50-GGTAGTCCATAGGCATTAGAAGG
Human IKKe KO: 50-GAACATCATGCGCCTCGTAGGGG
Human NEMO KO: 50-GGCAGCAGATCAGGACGTACTGG
Cells were transfected with PX458 vector containing particular
sgRNA using Lipofectamine 2000 (Invitrogene) according to the
manufacturer’s instructions. Green fluorescent protein (GFP)
expressing cells were sorted as single cell in 96-well plates using
FACSAria IIu (BD Biosciences). The resulting colonies were
screened for the expression of target proteins by immunoblotting
and sequencing of DNA surrounding the sgRNA target site.
Gene expression using retroviral vectors
Coding sequences of different proteins were inserted in retroviral
pBabe vector expressing GFP marker under SV40 promoter.
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modulating the assembly of IL-17RSC.
Upon binding of IL-17 to IL-17RA and IL-17RC, 6 molecules of ACT1 are recruited,
creating docking site for trimeric TRAF6. TRAF6-created K63-polyubiquitin
linkages promote activation of signaling pathways, but also trigger recruitment
of TBK1 and IKKe kinases to IL-17RSC. Both kinases then phosphorylate ACT1 in
disordered region of the protein. This leads to a spatial separation of
TRAF6-binding sites present on ACT1, decreased avidity for TRAF6 and its release
from IL-17RSC, ultimately leading to inhibition of signaling. In addition, TBK1/
IKKe enables recruitment of TRAF2 in kinase activity-independent manner to
promote stabilization of mRNA of target cytokines.
12 of 18 The EMBO Journal e104202 | 2020 ª 2020 The Authors
The EMBO Journal Helena Draberova et al
Mutations in these sequences were performed by fusion PCR
approach using Phusion polymerase (New England BioLabs). All
constructs were sequenced.
For production of viruses, ØNX-Eco cells (used for reconstitution
of ST2 cells) or ØNX-Ampho cells (used for reconstitution of HeLa
cells) were transfected with pBabe-GFP vector harboring coding
sequences for indicated proteins or empty vector using Lipofec-
tamine 2000. Virus containing supernatants were collected, passed
through 0.2 ll filter and added to target cells in the presence of
6 lg/ml polybrene followed by spinning 1,200 g for 45 min.
Infected cells were sorted as GFP positive using FACSAria IIu.
Production and testing of recombinant SF-IL-17
DNA sequences coding the SF-IL-17 construct containing from N-
terminus: CD33 leader, 6xHis, 2xStrep tag, 1xFlag tag, and either
murine IL-17 (AA 26–158) or human IL-17 (AA 24–155) were
prepared using GeneArt Gene Synthesis service (Thermo Fisher
Scientific) and inserted into pcDNA3.1 vector. These plasmids were
transfected to adherent HEK293 cells using polyethylenimine (PEI)
transfection; for transfection of the cells grown on one 15-cm dish,
we used 30 lg of the vector mixed with 75 lg PEI.
After 3 days, supernatants were collected and loaded on His
GraviTrap TALON column (GE Healthcare) equilibrated in purifica-
tion buffer (50 mM sodium phosphate pH 7.4, 300 mM NaCl).
Columns were subsequently washed with 20 mM imidazole in puri-
fication buffer and eluted with 350 mM imidazole in purification
buffer. In order to remove imidazol, samples were loaded on
centrifugal filter (10 kDa molecular weight cutoff, Merck Millipore),
washed several times with purification buffer and concentrated. The
protein concentration was measured using NanoDrop (ND-1000,
Thermo Fisher Scientific). Recombinant proteins were mixed with
equal volume of glycerol and kept at 80°C for long-term storage.
In order to check the production of SF-IL-17, samples were mixed
with SDS sample buffer, reduced with 50 mM dithiothreitol (DTT)
or left untreated, separated using SDS-PAGE and gels were stained
with InstantBlue Coomassie protein stain (Expedeon).
In order to test functionality of produced SF-IL-17, cells were
incubated on ice with SF-IL-17 (1 lg/ml) in FACS buffer (PBS/0.2%
FCS/0.1%NaN3) and washed and binding of SF-IL-17 was detected
using the APC-conjugated anti-Flag antibody on Accuri C6 cytome-
ter (BD Biosciences) and analyzed by FlowJo (BD Biosciences).
Cell stimulation
Prior to stimulation, ST2 or HeLa cells were washed and incubated
in serum-free DMEM medium for 30–60 min. In some experiments,
cells were pretreated with indicated chemical inhibitor. Depending
on whether murine or human cell line was used, cells were stimu-
lated with murine or human SF-IL-17, IL-1a, or TNF as indicated.
Subsequently, cells were lysed in 1% n-Dodecyl-b-D-Maltoside
(DDM) containing lysis buffer (30 mM Tris pH 7.4, 120 mM NaCl,
2 mM KCl, 2 mM EDTA, 10% glycerol, 10 mM chloroacetamide,
10 mM cOmplete protease inhibitor cocktail, and PhosSTOP tablets
(Roche)). Samples were incubated at 4°C for 30 min, cleared by
centrifugation (21,130 g, 30 min, 2°C), mixed with SDS sample
buffer, reduced by 50 mM DTT, and analyzed by immunoblotting.
Isolation of IL-17RSC
For each experimental condition, ST2 or HeLa cells were grown
on 15-cm dish. Cells were washed and incubated 30–60 min in
serum-free DMEM. In some experiments, cells were pretreated
with TBK1/IKKe inhibitor MRT67307 (2 lM). Cells were stimu-
lated in 10 ml serum-free DMEM with SF-IL-17 (500 ng/ml) for
indicated time points, solubilized in 1.5 ml 1% DDM containing
lysis buffer and cleared by centrifugation (21,130 g, 30 min, 2°C).
In control samples, 0.5 lg of SF-IL-17 was added post-lysis.
Cleared lysates were incubated with 10 ll of anti-FLAG M2 affin-
ity agarose gel (Sigma) overnight, washed 3× with 0.1% DDM
containing lysis buffer and eluted by boiling in SDS sample buffer
with 50 mM DTT.
Tandem affinity purification of IL-17RSC
For each experimental condition, ST2 cells were grown on
6 × 15 cm dishes. Prior to stimulation, cells were washed and
incubated in serum-free DMEM for 30–60 min. Cells were acti-
vated with murine SF-IL-17 (500 ng/ml) for 15 min or left
untreated. Subsequently, cells on each dish were solubilized in
1.5 ml of 1% DDM containing lysis buffer, collected, and incu-
bated for 30 min on ice. In total, for each experimental condition
9 ml of lysates were obtained. Samples were cleared by centrifu-
gation (21,130 g, 30 min, 2°C). In the control samples, 3 lg of
SF-IL-17 was added post-lysis.
The first immunoprecipitation step was carried out by overnight
incubation of samples with 50 ll of anti-FLAG M2 affinity agarose
gel (Sigma). Subsequently, the beads were washed 3× with 0.1%
DDM containing lysis buffer and isolated proteins were eluted by
incubation of the beads in 250 ll of 1% DDM containing lysis buffer
supplemented with 100 lg/ml of 3xFlag peptide (Sigma) overnight.
The supernatant was collected and the elution step was repeated
once again for 8 h.
The second purification step was carried upon incubation of the
samples with 50 ll of Strep-Tactin Sepharose beads (IBA Life-
sciences) overnight. The samples were subsequently washed 3×
with 0.1% DDM containing lysis buffer and 1× with lysis buffer
alone. Bound proteins were eluted upon incubation of the beads
with 220 ll of MS Elution buffer (2% sodium deoxycholate in
50 mM Tris pH 8.5).
Protein digestion
The eluted protein samples (200 ll) were reduced with 5 mM tris(2-
carboxyethyl)phosphine at 60°C for 60 min and alkylated with
10 mM methyl methanethiosulfonate at room temperature for
10 min. Proteins were cleaved overnight with 1 lg of trypsin
(Promega) at 37°C. In order to remove sodium deoxycholate,
samples were acidified with 1% trifluoroacetic acid, mixed with
equal volume of ethyl acetate, and centrifuged (15,700 g, 2 min)
and aqueous phase containing peptides was collected (Masuda et al,
2008). This step was repeated for two more times. Peptides were
desalted using in-house made stage tips packed with C18 disks
(Empore) (Rappsilber et al, 2007) and resuspended in 20 ll of 2%
acetonitrile with 1% trifluoroacetic acid.
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nLC-MS/MS analysis
The digested protein samples (12 ll) were loaded onto the trap
column (Acclaim PepMap 300, C18, 5 lm, 300 A˚ Wide Pore,
300 lm × 5 mm) using 2% acetonitrile with 0.1% trifluoroacetic
acid at a flow rate of 15 ll/min for 4 min. Subsequently, peptides
were separated on Nano Reversed phase column (EASY-Spray
column, 50 cm × 75 lm internal diameter, packed with PepMap
C18, 2 lm particles, 100 A˚ pore size) using linear gradient from 4 to
35% acetonitrile containing 0.1% formic acid at a flow rate of
300 nl/min for 60 min.
Ionized peptides were analyzed on a Thermo Orbitrap Fusion (Q-
OT-qIT; Thermo Scientific). Survey scans of peptide precursors from
350 to 1,400 m/z were performed at 120K resolution settings with a
4 × 105 ion count target. Four different types of tandem MS were
performed according to precursor intensity. First three types were
detected in Ion trap in rapid mode, and last one was detected in
Orbitrap with 15,000 resolution settings: (i) For precursors with
intensity between 1 × 103 to 7 × 103 with CID fragmentation (35%
collision energy) and 250 ms of ion injection time. (ii) For ions with
intensity in range from 7 × 103 to 9 × 104 with CID fragmentation
(35% collision energy) and 100 ms of ion injection time. (iii) For
ions with intensity in range from 9 × 104 to 5 × 106 with HCD frag-
mentation (30% collision energy) and 100 ms of ion injection time.
(iv) For intensities 5 × 106 and more with HCD fragmentation (30%
collision energy) and 35 ms of ion injection time. The dynamic
exclusion duration was set to 60 s with a 10 ppm tolerance around
the selected precursor and its isotopes. Monoisotopic precursor
selection was turned on. The instrument was run in top speed mode
with 3 s cycles.
Data analysis
All MS data were analyzed and quantified with the MaxQuant soft-
ware (version 1.6.5.0) (Cox et al, 2014). The false discovery rate
(FDR) was set to 1% for both proteins and peptides, and minimum
length was specified as seven amino acids. The Andromeda search
engine was used for the MS/MS spectra search against the murine
Swiss-Prot database (downloaded from Uniprot on June 2019).
Trypsin specificity was set as C-terminal to Arg and Lys, also allow-
ing the cleavage at proline bonds and a maximum of two missed
cleavages.
b-methylthiolation, N-terminal protein acetylation,
carbamidomethylation, Met oxidation, and eventually Ser/Thr/Tyr
phosphorylation, were included as variable modifications. Label-
free quantification was performed using intensity-based absolute
quantification (iBAQ) algorithm, which divides the sum of all
precursor-peptide intensities by the number of theoretically observ-
able peptides (Schwanhausser et al, 2011). Data analysis was
performed using Perseus 1.5.2.4 software (Tyanova et al, 2016).
Complex stoichiometry was estimated based on iBAQ intensity
ratio between individual components of the complex and IL-17RC.
The PCAs and heat maps were constructed in programming
language R. As source data, we used relative iBAQ values normal-
ized to IL-17RC with addition of pseudocount 0.001. These values
were log2-transformed prior to the analysis. The PCA was calculated
using prcomp function. The heat map was constructed using
heatmap.2 function available in gplots v3.0.1.1 package.
The analysis of ACT1 sequence to estimate the intrinsic disorder
was performed using programs SPOT disorder (Hanson et al, 2017),
MFDp2 (Mizianty et al, 2013), and IUPred2A (Meszaros et al, 2018).
RNA sequencing experiments
For the RNA sequencing experiment, ST2 cells were grown in 6-well
plates, washed, and stimulated with IL-17 (500 ng/ml) in the pres-
ence or absence of MRT67307 (2 lM) in DMEM supplemented with
0.5% FCS. Total RNA was extracted from the cells using RNeasy
Mini Kit (Qiagen) with on column DNAse treatment exactly accord-
ing the manufacturer0s protocol. The quality and quantity of isolated
RNA were evaluated using Nanodrop and TapeStation 2200 (Agilent
Technologies). The ensuing RNA sequencing analysis was based on
three independent experiments.
For each sample, 1 lg of total RNA (RIN > 7.0, rRNA ratio [28S:18S
rRNA] > 1.0) was sent to Macrogen Inc. for library preparation and
sequencing. Briefly, first TruSeq RNA stranded library was generated
and then sequencing was performed on the Illumina NovaSeq6000
with 100 bp paired-ends configuration, with about 30M reads per
sample. RNA was then quantified at the transcript-level using Salmon
(0.13.1) (Patro et al, 2017). First, a reference mouse transcriptome
from Gencode M21(GRCm38.p6) was created by combining the
sequence of protein-coding genes and long non-coding RNAs. Then,
the transcriptome was indexed using Salmon index with parameter “–
gencode”. Salmon quant was then run for each sample using parame-
ters “–gcBias”, “–validateMappings”, and “–allowDovetail”.
Transcript-level estimates from Salmon were summarized into
gene level estimates using tximport (Soneson et al, 2015); all genes
with at least 5 reads in at least 1 sample were retained for down-
stream analysis; with these parameters, 15,935 genes were obtained.
Differential gene expression analysis was performed using DESeq2
(Love et al, 2014), using independentFiltering and using the
Benjamini–Hochberg procedure to adjust P-values. Genes with
adjusted P-value < 0.01 are reported as statistically significant.
Quantitative real-time PCR
Cells were washed and incubated 30–60 min in DMEM supplemented
with 0.5% FCS. In some experiments, cells were pretreated with
TBK1/IKKe inhibitor MRT67307 (2 lM). Cells were stimulated with
SF-IL-17 (500 ng/ml) for 2 h and RNA was extracted with TRIzol
(Thermo Fisher Scientific) and purified using RNA clean & concentra-
tor kit (Zymo Research). Reverse transcription was performed with
RevertAid Reverse Transcriptase (Thermo Fisher Scientific) using
Oligo(dT)18 primers. Quantitative PCR was performed using SYBR
Master Mix (Top-Bio in Figs 2F and 4F or Roche in Figs EV2D and
EV3F) or and analyzed on LightCycler 480 (Roche). Data were
normalized to GAPDH. Following primer pairs for were used:
mGapdh: 50-TGCACCACCAACTGCTTAGC and 50-GGCATGGACT
GTGGTCATGAG
mCxcl1: 50-CTTGAAGGTGTTGCCCTCAG and 50-TGGGGACACC
TTTTAGCATC
mCxcl2: 50-CGGTCAAAAAGTTTGCCTTG and 50-TCCAGGTCAGT
TAGCCTTGC
mTnf: 50-CCACCACGCTCTTCTGTCTAC and 50-AGGGTCTGGGCCA
TAGAACT
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mIl6: 50-ATGGATGCTACCAAACTGGAT and 50-TGAAGGACTC
TGGCTTTGTCT
Statistics
The indicated statistical analyses were performed using Prism
(GraphPad Software). The experimental data that were analyzed by
unpaired two-tailed Student’s t-test were tested for normality as
follows: In Figs 1C, 2F, and EV3F data, normality was confirmed
using Kolmogorov–Smirnov test. In Figs 4F and EV2D, normal
distribution was assumed based on Fig 2F. In the case of Figs 3B
and EV3B, in which certain proteins were not detected and thus did
not follow normal distribution, two-tailed nonparametric Mann–
Whitney statistical tests were used.
Data availability
The datasets produced in this study are available in the following
databases: The mass spectrometry data: PRIDE PXD019020 (http://
www.ebi.ac.uk/pride/archive/projects/PXD019020). RNA-Seq data:
Gene Expression Omnibus GSE150410 (https://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?acc=GSE150410).
Expanded View for this article is available online.
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